摘要
目的 评价 1%派立明 (AZOPT)联合 0 2 5 %贝特舒点眼液每日两次点眼对原发性开角型青光眼、高眼压症及抗青光眼术后高眼压的降眼压效果及安全性。方法 12 0例 (171只眼 )纳入为期 2个月的前瞻性多中心研究。停用其他抗青光眼药物足够长的时间后 8Am～ 10Am间测量眼压的基础值 ,用药后每 2周在同一时段复查眼压一次共 2月 ,同时观察用药后的眼部及全身副作用。结果 用药前眼压为 2 5 41± 3 14mmHg ,4次随访眼压分别为 (18 3 8± 3 2 9,17 96± 3 18,17 84± 3 2 3 ,17 66± 2 97)mmHg ,与基础值比较差异有非常显著意义 (P <0 0 1)。平均眼压下降 7 45mmHg ,眼压下降率为 2 6 6%～ 3 0 5 %。少数病例出现眼部烧灼感、视物模糊、口苦等症状 ,均为轻度且能耐受 ,对视力、眼底无影响。结论 派立明与贝特舒联合用药具有稳定的降眼压效果及良好耐受性。
Objective To evaluate the efficacy and safety of 1% Brinzolamide(Azopt)combined with 0 25% Betoptic-S administered twice daily for 2-month in patients with primary open angle glaucoma(POAG)or ocular hypertension.Methods We performed a prospective,multicenter study of 171 eyes of 120 patients with PACG or ocular hypertension.Subjects were examined at baseline and every two weeks after treatment.Results Subjects had a mean reduction in IOP of 7 45mmHg.Azopt and Betoptic reduced intraocular pressure significantly at all time points.The IOP reduction rate was 26 6% to 30 5%.Our study indicates that Azopt and Betoptic provide a sustained long-term ocular hypotensive effect and are well tolerated causing only mild adverse effects that were generally local and transient.Conclusions 1% Azopt combined with 0 25% Betoptic-S demonstrated IOP-lowering efficacy and are well tolerated.
出处
《中国实用眼科杂志》
CSCD
北大核心
2004年第12期969-972,共4页
Chinese Journal of Practical Ophthalmology
